Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL) - A Randomised, Placebo Controlled Clinical Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Trial Profile

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL) - A Randomised, Placebo Controlled Clinical Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Exenatide (Primary)
  • Indications Cardiovascular disorders; Type 2 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms EXSCEL
  • Sponsors Amylin Pharmaceuticals; AstraZeneca; Bristol-Myers Squibb
  • Most Recent Events

    • 31 May 2017 Status changed from active, no longer recruiting to completed.
    • 23 May 2017 According to an AstraZeneca media release, results from this trial will be presented at the European Association for the Study of Diabetes (EASD) annual meeting on 14 September 2017.
    • 23 May 2017 Data from this trial published in an AstraZeneca Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top